Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+breast cancer

被引：0
|
作者：
Zhang, N. [1 ]
Xiang, Y. [1 ]
Jing, Z. [1 ]
Yu, F. [1 ]
Zeng, J. [1 ]
Pan, X. [1 ]
Zhou, W. [1 ]
Liang, X. [1 ]
Yue, Y. [1 ]
Zhang, H. [1 ]
Deng, Y. [1 ]
Deng, S. [1 ]
Mo, S. [1 ]
Jiang, X. [1 ]
Zeng, X. [1 ]
机构：
[1] Chongqing Univ, Breast Canc Ctr, Canc Hosp, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S249 / S249
页数：1
相关论文
共 50 条
  • [31] A pilot study of metabolomics biomarkers in breast cancer tumors treated with neoadjuvant therapy
    Zamora, P.
    Trilla-Fuertes, L.
    Zapater-Moros, A.
    Gamez-Pozo, A.
    Prado-Vazquez, G.
    Ferrer-Gomez, M.
    Diaz-Almiron, M.
    Lopez Vacas, R.
    Espinosa, E.
    Fresno Vara, J. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [32] An Appraisal of Clinicopathologic Parameters Associated with Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer
    Rong, Juan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 248 - 248
  • [33] An Appraisal of Clinicopathologic Parameters Associated with Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer
    Rong, Juan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 248 - 248
  • [34] Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+breast cancer
    Lammers, Philip E.
    Dank, Magdolna
    Masetti, Riccardo
    Abbas, Richat
    Hilton, Fiona
    Coppola, Jennifer
    Jacobs, Ira
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 266 - 273
  • [35] HER2+breast cancer treatment and cardiotoxicity: monitoring and management
    Jerusalem, Guy
    Lancellotti, Patrizio
    Kim, Sung-Bae
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (02) : 237 - 250
  • [36] Biomarkers involved in the neoadjuvant therapy response in triple-negative and Her2+subtypes breast cancer.
    Bofill, Salvador
    Benavent, Marta
    Gil, Ana
    Pineda, Antonia
    Molina-Pinelo, Sonia
    Gonzalez, Rosario
    Montano, Alvaro
    Ruiz Borrego, Manuel
    Falcon, Alejandro
    Garrigos, Carmen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.
    Ding, Xiaowen
    Mo, Wenju
    Xie, Xiaohong
    Wang, Ouchen
    Ding, Yuqin
    Zhao, Shuai
    He, Xiangming
    Feng, Weiliang
    Zou, Dehong
    Yang, Hongjian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Breast MRI as a radiomic biomarker of immune response in HER2+breast cancer
    Kennedy, Laura Carpin
    Durenberger, Grace
    Stanton, Sasha E.
    Vinayak, Shaveta
    Dintzis, Suzanne
    Partridge, Savannah
    Gadi, V. K.
    CANCER RESEARCH, 2020, 80 (04)
  • [39] Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+breast cancer
    LeVee, Alexis
    Spector, Kellie
    Larkin, Brigid
    Dezem, Felipe
    Plummer, Jasmine
    Dadmanesh, Farnaz
    Patil, Sujata
    McArthur, Heather L. L.
    CANCER MEDICINE, 2023, 12 (09): : 10647 - 10659
  • [40] Genomic alterations associated with HER2+breast cancer risk and clinical outcome in response to trastuzumab
    Singla, Heena
    Kaur, Raman Preet
    Shafi, Gowhar
    Vashistha, Rajesh
    Banipal, Raja Paramjeet Singh
    Kumar, Vinod
    Munshi, Anjana
    MOLECULAR BIOLOGY REPORTS, 2019, 46 (01) : 823 - 831
12345